Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Smoking cessation 

Smoking cessation drug linked to cardiovascular adverse events

In a study of new varenicline users, researchers found that the incidence of cardiovascular events was 34% higher during the 12-week treatment period than in the year before or after use

Varenicline smoking cessation tablets

Source: GIPhotoStock / Science Photo Library

Researchers observed new varenicline users from the one year before to one year after use to investigate the link between varenicline and cardiovascular adverse events 

Varenicline has been shown to improve smoking cessation rates over other pharmacological and non-pharmacological methods. However, concerns have been raised over its link to serious cardiovascular and neuropsychiatric events.

In the American Journal of Respiratory and Critical Care Medicine (online, 20 December 2017), researchers carried out a study involving data on 56,851 new varenicline users, who were observed from one year before to one year after varenicline use[1]. The incidence of adverse events during their 12-week treatment period (risk period) was compared with the remaining observation period (control period).

They found that the incidence of cardiovascular events was 34% higher in the risk period compared with the control period. There was also a small association between varenicline use and neuropsychiatric events, but this was found to be of questionable clinical significance and was not robust in sensitivity analyses.

The team said the findings supported an association between varenicline and cardiovascular adverse events, and the risks should be weighed against the benefit of the drug for individual patients.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2018.20204345

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Clinical Pharmacokinetics

    Clinical Pharmacokinetics

    A practical guide to the use of pharmacokinetic principles in clinical practice. Includes case studies with questions and answers.

    £33.00Buy now
  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Varenicline smoking cessation tablets

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.